HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.

Abstract
We present the design of a double-blind, randomised placebo-controlled phase III study to evaluate safety and efficacy of IVIG in the treatment of patients suffering from primary or secondary chronic progressive multiple sclerosis. The primary endpoint is disability. Two measures of disability were chosen in order to assess the primary end point (a) sustained improvement (assessed at month 6, confirmed at month 9) and (b) progression to increasing disability of the disease (sustained for 3 months) at any time during the course of this 2 years study. The disability is measured by the Extended Disability Status Scale (EDSS). Secondary end points include the assessment of visual function, functions of the upper extremity, cognitive functions, depression and quality of life.
AuthorsD Poehlau, J Federlein, T Postert, M Sailer, F Bethke, L Kappos, J Haas, H Przuntek
JournalMultiple sclerosis (Houndmills, Basingstoke, England) (Mult Scler) Vol. 3 Issue 2 Pg. 149-52 (Apr 1997) ISSN: 1352-4585 [Print] England
PMID9291171 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunoglobulins, Intravenous
  • Placebos
Topics
  • Adult
  • Aged
  • Disability Evaluation
  • Double-Blind Method
  • Humans
  • Immunoglobulins, Intravenous (adverse effects, therapeutic use)
  • Middle Aged
  • Multiple Sclerosis (physiopathology, therapy)
  • Patient Selection
  • Placebos
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: